Lumiliximab (Anti-CD23 Recombinant Antibody) is an anti-CD23 monoclonal antibody that inhibits allergen-induced responses[1].
References
[1] Poole JA, et al. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol. 2005 Oct;116(4):780-8. DOI:10.1016/j.jaci.2005.07.007
